AUG 26·SEC EDGARLow
Kiai Parsa purchased $52K of MED (indirect holdings)
Kiai Parsa purchased 4,329 indirectly-held shares of MEDIFAST INC (MED) at $12.00 across 2 trades on 2026-08-24.
StockNYSE · US · USDConsumer Cyclical · Personal Services
$MED
MEDIFAST INC
Price · $MEDvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $MED in the last 7 days.
Insider · 30dAll trades →
- Buys
- $895K 6 txs
- Sells
- — 0 txs
Kiai Parsa6× · $895K
10b5-1 share of filings0%
Top stories · $MEDMore →
AUG 21·SEC EDGAR
Kiai Parsa purchased $843K of MED (indirect holdings)
Kiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.
AUG 4·financialcontent.com
Why Medifast (MED) Stock Is Trading Up Today
Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
MED sentiment & insider activity
Recent MED coverage spans earnings, financial news and insider activity.
In the last 30 days, MED insiders filed 6 SEC Form 4 transactions — 6 purchases ($895K) and no sales. The most active reporter was Kiai Parsa with 6 filings.
What's driving MED
Small insider purchase may signal confidence but limited price impact.
Insider purchase signals confidence but size is modest.
The earnings beat plus a sharply higher-than-expected GAAP EPS outlook is the immediate driver of repricing, with follow-through risk if margins or demand do not support the forecast.
The article’s new, decision-relevant inputs are the Q2 beat, the next-quarter revenue midpoint, and the GAAP EPS loss versus consensus, all tied to an immediate +12.8% move.
The filing discloses a sharp YoY revenue decline tied to fewer active earning coaches, plus a cash-rich, debt-free balance sheet and explicit Q3 and FY 2026 loss guidance.
alphai scores every news story that mentions MED with an AI model for sentiment and relevance, and aggregates insider trades from MEDIFAST INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $MED
Score
Kiai Parsa purchased $52K of MED (indirect holdings)
Kiai Parsa purchased 4,329 indirectly-held shares of MEDIFAST INC (MED) at $12.00 across 2 trades on 2026-08-24.
1 min readKiai Parsa purchased $843K of MED (indirect holdings)
Kiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.
1 min read
Why Medifast (MED) Stock Is Trading Up Today
Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.
4 min read
Medifast (NYSE:MED) Beats Expectations in Strong Q2 CY2026, Stock Jumps 12.8%
Medifast (NYSE:MED) reported Q2 CY2026 revenue of $76.38M, down 27.6% year over year but 5.1% above expectations. Next-quarter revenue guidance was $70M at the midpoint, about 3.4% above analyst estimates. GAAP EPS loss was $0.28, worse than consensus. Shares rose 12.8% to $10.99.
3 min readMEDIFAST INC (MED): Results of Operations and Financial Condition
MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter
6 min read
Earnings To Watch: Medifast (MED) Reports Q2 Results Tomorrow
Medifast (NYSE: MED) will report Q2 results Monday after market hours. The prior quarter revenue was $76.04 million, down 34.3% year over year, and EPS guidance for next quarter exceeded analysts’ expectations. For the upcoming quarter, analysts expect revenue down 31.1% year over year. MED shares are down 10.9% over the past month; average price target is $12 vs $9.83.
4 min read
MED Q2'26 Earnings: EPS estimate is (0.65) USD
Medifast Inc. (MED) is scheduled to report Q2 2026 earnings on Aug. 3 after the market closes, with results expected at 4:05 PM ET. The consensus estimates call for revenue of $72.70 million and EPS of -$0.65 for the quarter, according to the article.
1 min read
Medifast director Scott Schlackman buys $62,950 in company stock
Medifast director Scott Schlackman recently purchased 5,000 shares of company stock in two transactions totaling $62,950, increasing his direct holdings to over 30,500 shares. These purchases occurred as Medifast's stock has risen 17.7% year-to-date, despite a weak financial health rating. The company also recently reported mixed Q1 2026 earnings, beating EPS estimates but missing revenue projections.
2 min read
Medifast Inc reports results for the quarter ended March 31 - Earnings Summary
Medifast Inc. (MED) has released its earnings summary for the quarter that ended on March 31. This report provides key financial performance indicators for the company during that period. The full details are available through Thomson Reuters.
2 min read
Medifast (MED) to Release Earnings on Monday
Medifast (NYSE:MED) is scheduled to release its Q1 2026 earnings after market close on Monday, April 27th, with analysts expecting a loss of ($0.55) per share on $69.20 million in revenue. The company recently posted Q4 results where it beat analyst estimates, reporting ($0.55) EPS for the quarter. Several analysts have adjusted their ratings and price targets for Medifast, with a consensus "Reduce" rating and a $12.00 target price.
2 min read